Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc. (49J)

Market Closed
3 Jun, 17:33
XDUS XDUS
13. 30
-0.3
-2.21%
- Market Cap
- P/E Ratio
- Div Yield
387 Volume
- Eps
13.6
Previous Close
Add Transaction
Day Range
13.3 13.9
Year Range
12.1 35
Want to track 49J and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

49J closed today lower at €13.3, a decrease of -2.21% from yesterday's close, completing a monthly decrease of -14.19% or -€2.2. Over the past 12 months, 49J stock lost -41.15%.
49J is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on XDUS (EUR).

49J Chart

Caris Life Sciences, Inc. (49J) FAQ

What is the stock price today?

The current price is €13.30.

On which exchange is it traded?

Caris Life Sciences, Inc. is listed on XDUS.

What is its stock symbol?

The ticker symbol is 49J.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Caris Life Sciences, Inc. ever had a stock split?

No, there has never been a stock split.

Caris Life Sciences, Inc. Profile

- Industry
- Sector
Dr. David Dean Halbert M.D. CEO
XDUS Exchange
- ISIN
United States Country
1,769 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Caris Life Sciences is a pioneering AI-driven precision medicine company dedicated to transforming the healthcare landscape through meticulous molecular profiling and sophisticated machine learning techniques. Specializing in the in-depth analysis of cancer at the molecular level, Caris employs advanced methods such as whole exome and whole transcriptome sequencing using patient tissue and blood samples. The company's innovative approach has enabled it to cultivate one of the world's largest multimodal clinico-genomic databases, which integrates genomic, transcriptomic, and proteomic data along with clinical outcomes, encompassing over 740,000 matched patient records.

Founded in 2008 and headquartered in Irving, Texas, Caris Life Sciences operates on an international scale, with offices in prominent medical and research hubs. The company's commitment to precision medicine is evident in its array of solutions that empower oncologists and patients, providing essential molecular information that supports therapy selection, enhances drug development, and fosters early disease detection.

Products and Services

  • MI Profile
    MI Profile is Caris’ flagship tissue-based profiling solution that utilizes comprehensive molecular profiling techniques to analyze tumor biology. This service aids in understanding the specific characteristics of a patient’s cancer and helps guide personalized treatment plans tailored to individual patient needs.
  • Caris Assure
    Caris Assure offers blood-based analysis for cancer assessment, leveraging advanced techniques to evaluate the molecular landscape of cancer through liquid biopsies. This non-invasive service allows clinicians to gather important molecular data without the need for invasive tissue collection, facilitating easier monitoring of patients’ conditions over time.
  • Caris Detect
    Caris Detect is a multi-cancer early detection assay that employs ultra-deep whole genome sequencing to identify signs of cancer at its earliest stages. This innovative blood test is designed to provide oncologists with critical insights that can lead to prompt diagnosis and timely intervention, potentially improving patient outcomes.

Contact Information

Address: 750 West John Carpenter Freeway
Phone: 866 771 8946